共 50 条
Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne
被引:0
|作者:
Del Rosso, James
[1
,2
,3
]
Gold, Linda Stein
[4
]
Tyring, Stephen
[5
]
Zeichner, Joshua
[6
]
Callender, Valerie
[7
,8
]
Draelos, Zoe
[9
]
Werschler, William
[10
]
Cook-Bolden, Fran
[11
]
Guenin, Eric
[12
]
机构:
[1] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV 89149 USA
[2] Adv Dermatol & Cosmet Surg, Maitland, FL 32751 USA
[3] Tour Univ Nevada, Henderson, NV 89014 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Callender Dermatol & Cosmet Ctr, Glenn Dale, MD USA
[8] Howard Univ, Coll Med, Washington, DC USA
[9] Dermatol Consulting Serv PLLC, High Point, NC USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Weill Cornell, Dept Dermatol, New York, NY USA
[12] Ortho Dermatol, Bridgewater, NJ USA
关键词:
QUALITY-OF-LIFE;
TOPICAL RETINOIDS;
DOUBLE-BLIND;
VULGARIS;
MULTICENTER;
ADAPALENE;
SKIN;
D O I:
暂无
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background: While topical retinoids are a mainstay of acne treatment, acne can manifest differently in various skin types. The objective of these post hoc analyses from two pooled phase 3 studies was to examine efficacy and safety of tazarotene 0.045% and quality of life improvements in self-identified Caucasian adults with moderate-to-severe acne. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged >= 9 years with moderateto-severe acne were randomized (1:1) to tazarotene 0.045% lotion or vehicle lotion (N=1,614); a subset of adults (>= 18 years) who selfreported Caucasian (White) race (n=645) were examined. Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment (endpoint) success (>= 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear]). Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed. Results: At week 12, tazarotene lotion significantly reduced lesion counts by 60% (least-squares mean percent changes from baseline, tazarotene vs vehicle: inflammatory, -61.2% vs -51.1%; noninflammatory, -59.7% vs -49.3%; P<0.001, both). Significantly more participants achieved treatment success with tazarotene lotion versus vehicle (P<0.001). Numerical improvements in qualityof-life domains were observed from baseline to week 12. Most TEAEs were unrelated to treatment, and rates of moderate-to-severe erythema decreased from baseline to week 12 with tazarotene treatment. Conclusions: Tazarotene 0.045% lotion was efficacious and well tolerated over 12 weeks and led to quality-of-life improvements in Caucasian adults with moderate-to-severe acne. These results, along with those from patients with skin of color, demonstrate that once daily tazarotene 0.045% lotion is an effective and well-tolerated treatment option regardless of race or skin color.
引用
收藏
页码:1061 / 1069
页数:9
相关论文